APOE4/4 is linked to damaging lipid droplets in Alzheimer's microglia.

Several genetic risk factors for Alzheimer's Disease (AD) implicate genes involved in lipid metabolism and many of these lipid genes are highly expressed in glial cells. However, the relationship between lipid metabolism in glia and AD pathology remains poorly understood. Through single-nucleus RNA-sequencing of AD brain tissue, we have identified a microglial state defined by the expression of the lipid droplet (LD) associated enzyme ACSL1 with ACSL1-positive microglia most abundant in AD patients with the APOE4/4 genotype. In human iPSC-derived microglia (iMG) fibrillar Aß (fAß) induces ACSL1 expression, triglyceride synthesis, and LD accumulation in an APOE-dependent manner. Additionally, conditioned media from LD-containing microglia leads to Tau phosphorylation and neurotoxicity in an APOE-dependent manner. Our findings suggest a link between genetic risk factors for AD with microglial LD accumulation and neurotoxic microglial-derived factors, potentially providing novel therapeutic strategies for AD.

Paradoxical kinesia in Parkinson's disease revisited: Anticipation of temporal constraints is critical.

Slowness of movement, called bradykinesia is the cardinal symptom of Parkinson's disease. Under distinct but not yet well-defined circumstances, patients with Parkinson's disease are able to overcome bradykinesia. One common hypothesis for this phenomenon termed paradoxical kinesia in Parkinson's disease postulates that the presentation of external sensory triggers is pivotal to elicit significant increase of motor velocity. In the present study, we examined an alternative hypothesis, namely that an internal cue in the absence of sensory cues are linked to paradoxical kinesia. To test this alternative hypothesis, patients with Parkinson's disease and healthy age-matched controls (n=9 per group) performed two movement tasks. In the stationary-object prehension task, subjects had to pick up a stationary target object. For the escaping-object task, the participants had to pick up the target object before it moved out of reach. The time available to reach for the object was adjusted individually to ensure comparable difficulty across participants. Reaction time, movement duration, and maximum velocity were assessed for both movement tasks. In Parkinson's disease patients and healthy controls, anticipation of the imminent movement of a target object significantly decreased reaction time, movement duration, and increased maximum movement velocity. The increase of maximum movement velocity in the escape-condition was significantly more pronounced for Parkinson's disease patients as compared to healthy controls. We provide evidence that internal cues such as temporal constraints are sufficient to diminish the cardinal clinical symptom of bradykinesia in Parkinson's disease. Our results suggest that expectations rather than sensory cues are critical for the emergence of paradoxical kinesia and we discuss the implications of our findings for an account of paradoxical kinesia.

Posttranslational modification and mutation of histidine 50 trigger alpha synuclein aggregation and toxicity.

BACKGROUND: Aggregation and aggregation-mediated formation of toxic alpha synuclein (aSyn) species have been linked to the pathogenesis of sporadic and monogenic Parkinson's disease (PD). A novel H50Q mutation of aSyn, resulting in the substitution of histidine by glutamine, has recently been identified in PD patients. We have previously shown that the lipid peroxidation product 4-hydroxy-2-nonenal (HNE) induces the formation of HNE-aSyn adducts, thereby promoting aSyn oligomerization and increasing its extracellular toxicity to human dopaminergic neurons. Intriguingly, we identified histidine 50 (H50) of aSyn as one of the HNE modification target residues. These converging lines of evidence support the hypothesis that changes in H50 via posttranslational modification (PTM) and mutation trigger the formation of aggregated, toxic aSyn species, which interfere with cellular homeostasis. In the present study, we aim to elucidate 1) the role of H50 in HNE-mediated aSyn aggregation and toxicity, and 2) the impact of H50 mutation on aSyn pathology. Besides the PD-related H50Q, we analyze a PD-unrelated control mutation, in which H50 is replaced by an arginine residue (H50R). RESULTS: Analysis of HNE-treated aSyn revealed that H50 is the most susceptible residue of aSyn to HNE modification and is crucial for HNE-mediated aSyn oligomerization. Overexpression of aSyn with substituted H50 in H4 neuroglioma cells reduced HNE-induced cell damage, indicating a pivotal role of H50 in HNE modification-induced aSyn toxicity. Furthermore, we showed in vitro that H50Q/R mutations substantially increase the formation of high density and fibrillar aSyn species, and potentiate the oligomerization propensity of aSyn in the presence of a nitrating agent. Cell-based experiments also revealed that overexpression of H50Q aSyn in H4 cells promotes aSyn oligomerization. Importantly, overexpression of both H50Q/R aSyn mutants in H4 cells significantly increased cell death when compared to wild type aSyn. This increase in cell death was further exacerbated by the application of H2O2. CONCLUSION: A dual approach addressing alterations of H50 showed that either H50 PTM or mutation trigger aSyn aggregation and toxicity, suggesting an important role of aSyn H50 in the pathogenesis of both sporadic and monogenic PD.

Studying neurodegenerative diseases in culture models

Neurodegenerative diseases are pathological conditions that have an insidious onset and chronic progression. Different models have been established to study these diseases in order to understand their underlying mechanisms and to investigate new therapeutic strategies. Although various in vivo models are currently in use, in vitro models might provide important insights about the pathogenesis of these disorders and represent an interesting approach for the screening of potential pharmacological agents. In the present review, we discuss various in vitro and ex vivo models of neurodegenerative disorders in mammalian cells and tissues.